Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes

Molecular and Cellular Biochemistry

Volumn 305, Issue 1-2, 2007, Pages 123-131

  Han, Yingchun ^a   Randell, Edward ^a   Vasdev, Sudesh ^b   Gill, Vicki ^b   Gadag, Vereesh ^a   Newhook, Leigh Anne ^a   Grant, Marie ^c   Hagerty, Donna ^c  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c Eastern Health Canada   (Canada)

Author keywords

Glyoxal; Methylglyoxal; Na+ K+ ATPase activity; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM); ADVANCED GLYCATION END PRODUCT; GLUCOSE; GLYOXAL; HEMOGLOBIN A1C; MEMBRANE ENZYME; METHYLGLYOXAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ERYTHROCYTE MEMBRANE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PROGNOSIS; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; CELL MEMBRANE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; ERYTHROCYTES; FEMALE; GLYOXAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MODELS, BIOLOGICAL; PYRUVALDEHYDE; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 34948816643     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-007-9535-1     Document Type: Article

References (62)

1. World Health Organization (2006) Diabetes Fact Sheet. 312 www.who.int/ mediacentre/factsheet/fs312/en/print.html (accessed March 29, 2007)
2. American Diabetes Association (2007) All about diabetes. www.diabetes.org/about-diabetes.jsp (accessed March 29, 2007)
3. Thornalley PJ, Langborg AM, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116
4. Thornalley PJ (2005) Dicarbonyl intermediates in the maillard reaction. Ann NY Acad Sci 1043:111-117
5. Phillips SA, Thornalley PJ (1993) The formation of methylgyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212:101-105
6. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995) Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochem 34:3702-3709
7. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS (2001) Alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732
8. Chang KC, Paek KS, Kim HJ, Lee YS, Yabe-Nishimura C, Seo HG (2002) Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 61:1184-1191
9. Kalapos MP (1999) Methylglyoxal in living organisms. Chemistry, biochemistry, toxicology and biological implications. Toxic Let 110:145-175
10. Jay D, Hitomi H, Griendling KK (2006) Oxidative stress and diabetic cardiovascular complications. Free Rad Biol Med 41:183-192
11. Kershnar AK, Daniels SR, Imperatore G, Palla SL, Petitti DB, Petitti DJ, Marcovina S, Dolan LM, Hamman RF, Liese AD, Pihoker C, Rodriguez BL (2006) Lipid abnormalities are prevalent in youth with Type 1 and Type 2 diabetes: The search for diabetes in youth study. J Pediatr 149:314-319
12. O'Brien PJ, Siraki AG, Shangari N (2005) Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 35:609-662
13. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spec. Biochem J 375:581-592
14. Zeng J, Davies MJ (2005) Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of α-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 18:1232-1241
15. Morgan PE, Dean RT, Davies MJ (2002) Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 403:259-269
16. Park YS, Koh YH, Takahashi M, Miyamoto Y, Suzuki K, Dohmae N, Takio K, Honke K, Taniguchi N (2003) Identification of the binding site of methylglyoxal on glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites Arg 184 and 185. Free Rad Res 37:205-211
17. 2+-ATPase. Diabetes 53:463-473
18. Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ (2005) Methylglyoxal can modify GAPDH activity and structure. Ann NY Acad Sci 1043:135-145
19. Jia X, Olson DJH, Ross ARS, Wu L (2006) Structural and functional changes in human insulin induced by methylglyoxal. FASEB J 20:E871-E879
20. Horiuchi S, Sakamoto Y, Sakai M (2003) Scavenger receptors for oxidized and glycated proteins. Amino Acids 25:283-292
21. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886
22. Xu B, Chibber R, Ruggerio D, Kohner E, Ritter J, Ferro A (2003) Impariment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 17:1289-1291
23. Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M, Dincer UD, Besch HR Jr (2003) Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52:1825-1836
24. Ferretti G, Bacchetti T,Marchionni C, Calderelli L, Curatola G (2001) Effect of glycation of high density lipoproteins on their physiochemical properties and on paraoxonase activity. Acta Diabetol 38:163-169
25. ω-carboxymethylarginine as a novel acid-labile advanced glycation end product in collagen. Biochem J 347:23-27
26. 1 production in macrophage RAW cells. J Lab Clin Med 141:242-249
27. Rashid G, Benchetrit S, Fishman D, Bernheim J (2004) Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells. Kid Int 66:1099-1106
28. Rodriguez-Manas L, Angulo J, Vallejo S, Peiro C, Sanchez-Ferrer A, Cercas E, Lopez-Doriga P, Sanchez-Ferrer CF (2003) Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 46:556-566
29. Wautier JL, Schmidt AM (2004) Protein glycation. A firm link to endothelial cell dysfunction. Circ Res 95:233-238
30. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM (2001) Receptor for advanced glycation end products medicates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21:905-910
31. II in neonatal mesangial cells. Am J Physiol (Renal Physiol) 278:F676-F683
32. Wu L (2005) The pro-oxidant role of methylglyoxal in mesenteric artery smooth muscle cells. Can J Physiol Pharmacol 83:63-68
33. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF (2005) Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol (Renal Physiol) 289:420-430
34. ε-(carboxymethyl)lysine independently of glycohaemoglobin concentration. Diabetologia 42:603-607
35. Misselwitz J, Franke S, Kauf E, John U, Stein G (2002) Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr Nephrol 17:316-321
36. ε -(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: Correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 19:631-636
37. ε-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 7:263-267
38. +-ATPase activity, metabolic control, and neuropathy in IDDM patients. Diabetes Care 19:564-568
39. Mimura M, Makino H, Kanatsuka A, Asai T, Yoshida S (1994) Reduction of erythrocyte (Na(+)-K)ATPase activity in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Horm Met Res 26:33-38
40. Djemli-Shipkolye A, Coste T, Raccah D, Vague P, Pieroni G, Gerbi A (2001) Na,K-ATPase alterations in diabetic rats: Relationship with lipid metabolism and nerve physiological parameters. Cell Mol Biol 47:297-304
41. Tsimaratos M, Coste TC, Djemli-Shipkolye A, Daniel L, Shipkolye F, Vague P, Raccah D (2001) Evidence of time-dependent changes in renal medullary Na,K-ATPase activity and expression in diabetic rats. Cell Mol Biol 47:239-245
42. Koc B, Erten V, Yilmaz MI, Sonmez A, Kocar IH (2003) The relationship between red blood cell NA/K-ATPase activities and diabetic complications in patients with type 2 diabetes mellitus. Endocrine 21:273-278
43. Clinical Practice Guidelines Expert Committee of Canadian Diabetes Association (2003) Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27:S
44. +-ATPase activity with an automated analyzer. Clin Chem 43:1986-1987
45. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
46. McLellan AC, Thornalley PJ, Benn J, Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87:21-29
47. Nemet I, Turk Z, Duvnjak L, Varga-Defterdarovic L (2005) Humoral methylglyoxal level reflects glycemic fluctuation. Clin Biochem 38:379-383
48. 1 β-dicarbonyl compound levels un human uremic plasma: Specific in vivo determination on intermediates in advanced maillard reaction. Biochem Biophys Res Comm 256:89-93
49. Lapolla A, Flamini R, Vedova AD, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R, Traldi P (2003) Glyoxal and methylglyoxal levels in diabetic patients: Quantitive determination by a new GC/MS method. Clin Chem Lab Med 41:1166-1173
50. Elhadd TA, Kennedy G, Hill A, McLaren M, Newton RW, Greene SA, Belch JJF (1999) Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with Type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 15:405-411
51. Mostafa AA, Randell EW, Vasdev SC, Gill VD, Han Y, Gadag V, Raouf AA, El Said H (2007) Plasma protein advanced glycation end products, carboxymethyl cysteine and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem, doi. 10.1007/s11010-007-9422-9
52. +-pumping activity in erythrocytes from IDDM and NIDDM subjects. Diabetes 38:825-831
53. Besch W, Blucher H, Bettin D, Wolf E, Michaelis D, Kohnert KD (1995) Erythrocyte sodium-lithium countertransport, adenosine triphosphatase activity and sodium-potassium fluxes in insulin-dependent diabetes. Int J Clin Lab Res 25:104-109
54. +) ATPase activity in Type 1 (insulin-dependent) diabetic subjects and its activation by homologous plasma. Diabetologia 29:623-628
55. Jannot MF, Raccah D, Dufayet de la Tour D, Coste T, Vague P (2002) Genetic and environment regulation of NA/K adenosine triphosphatase activity in diabetic patients. Metabolism 51:284-291
56. 1c levels and erythrocyte transport functions in complication-free type 1 diabetic children and adolescents. Acta Diabetol 40:9-13
57. Stark G (2005) Functional consequences of oxidative membrane damage. J Membrane Biol 205:1-16
58. Chang CT, Wu MS, Tian YC, Chen KH, Yu CC, Liao CH, Hung CC, Yang CW (2007) Enhancement of epithelial sodium channel expression in renal cortical collecting duct cells by advanced glycation end products. Nephrol Dian Transplant 22:722-731
59. Barbagallo M, Gupta RK, Resnick LM (1993) Independent effects of hyperinsulinemia and hyperglycemia on intracellular sodium in normal human red cells. Am J Hypertens 6:264-267
60. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V (2000) Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens 18:567-573
61. Midaoui AEL, Elimadi A, Wu L, Haddad PS, de Champlain J (2003) Lipoic acid prevents hypertension, hyperglycemia and the increase in heart mitochondrial superoxide production. Am J Hypertens 16:173-179
62. Foster TS (2007) Efficacy and safety of α-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Edu 33:111-117